Epigenomics AG And Academic Partners Receive BMBF Grant To Develop Novel Techniques For Early Cancer Detection Based On DNA-Methylation
10/19/2005 5:11:04 PM
Epigenomics AG today announced the receipt of BMBF (German Ministry for Education and Research) funding for a three-year project to design and develop new techniques for high-throughput early cancer screening based on DNA methylation, a natural “switch” that controls gene expression.
The BMBF, through its BioChance Plus programme, will contribute €1.1 million of the estimated €2.7 million project total. The project will be conducted in collaboration with the teams of Prof. Albert Jeltsch, International University of Bremen (IUB) and Prof. Jörn Walter, a co-founder of Epigenomics and now at the Universität des Saarlandes, two leading academic groups involved in the DNA methylation field. The award was presented yesterday by Secretary of State Christoph Matschie to Kurt Berlin, PhD, Chief Scientific Officer of Epigenomics, during the opening of the BMBF Biotechnology Days 2004 that are currently held in Jena, Germany.
comments powered by